TOKYO, Mar 9, 2022 - (JCN Newswire) - Showa Denko K.K. (SDK) (TOKYO: 4004) announces that it was resolved at the Board of Directors meeting held today that, regarding a plan for transformation from current company structure to holding company structure, the Company will start to consider the plan and prepare for execution of the plan. Execution of the plan is subject to adoption of relevant resolutions by shareholders at an extraordinary general meeting of shareholders, which is planned to be held in late September 2022, and is also subject to approval and authorization by the appropriate authorities. We will announce details of the plan as soon as they are decided.

1. Background and purpose of the consideration

As we stated in "Our Policy toward Realization of 'Co-Creative Chemical Company'," which was announced on February 14, 2022, the Showa Denko Group aims to change the Group into "Company that can compete on the world stage," "Company that contributes to sustainable global society," and "Company that develops talent that represents Japan's manufacturing industry," thereby making the Group "Global Top-Level Functional Chemical Manufacturer from Japan," which is the ideal state of the Co-Creative Chemical Company.

Into the Purpose of the Showa Denko Group, which is "Change society through the power of chemistry," we put our will to have global top-level competence as a chemical manufacturer, to think beyond the conventional boundaries of our individual business activities, and to co-create better society with stakeholders and communities who share a high aim and ideal with us. This is the essence of Co-Creative Chemical Company that we aim to be. Through realization of the Purpose, the Showa Denko Group will continue reforming itself, aiming to become the Global Top-Level Functional Chemical Manufacturer.

In the process to realize the ideal state, the Showa Denko Group will commit itself to realize scale and profitability of the Company which are prerequisites to become a company that can compete on the world stage, execute business portfolio management focusing on strategic allocation of management resources, while maintaining integrity, promoting innovations that bear competitive advantage, and executing personnel strategy focusing on human resource development based on Purpose and Four Values, which are the Showa Denko Group's new Corporate Philosophy.

To become Global Top-Level Functional Chemical Manufacturer, which is our ideal state, and to maximize our corporate value, we will accelerate business portfolio management which enable us to solve global social issues and create sustainable corporate value. Aiming to establish organizational structure optimum for realization of the ideal state, we will consider specific procedures for transformation into a holding company structure.

If the Group transforms itself into a holding company structure, the holding company will specialize in formulating and executing group strategy and functioning as a company listed on the stock exchange. The holding company will cope with management issues quickly and flexibly, and realize appropriate allocation of management resources group-wide from bird's-eye viewpoint, including formation of business alliance and M&A. The newly integrated company (a company involved in manufacturing) will focus on strengthening competitiveness of each business of the Company in order to realize synergy of integration of Showa Denko and Showa Denko Materials as soon as possible, and operate businesses in a quick and flexible manner corresponding to the surrounding environment, thereby enhancing corporate value of the entire Group.

2. Planned process for transformation into holding company structure

The planned process for transformation from current company structure to holding company structure is as follows. We will set the current Showa Denko K.K. as a company to be split, execute the company split, make Showa Denko Materials Co., Ltd. (SDMC), which is a wholly owned subsidiary of HC Holdings K.K. (HCHD), in which SDK holds 100% of voting rights, succeed all businesses currently operated by SDK, and merge HCHD into SDMC. Then we will set SDMC as a company to be split, execute the company split, and make SDK succeed a part of SDMC's assets and liabilities. We will announce the detail of this process as soon as it is decided in the future.

3. Plan for the future

- End of June 2022: Record Date to fix shareholders who can execute voting rights at the extraordinary general meeting of shareholders concerning transformation into holding company structure
- August 2022: Board of Directors' meeting concerning transformation into holding company structure
- September 2022: Extraordinary general meeting of shareholders concerning transformation into holding company structure
- January 2023: Transformation into a holding company structure

About Showa Denko K.K.

Showa Denko K.K. (SDK; TSE:4004, ADR:SHWDY) is a major manufacturer of chemical products serving from heavy industry to computers and electronics. The Petrochemicals Sector provides cracker products such as ethylene and propylene, the Chemicals Sector provides industrial, high-performance and high-purity gases and chemicals for semicon and other industries, the Inorganics Sector provides ceramic products, such as alumina, abrasives, refractory/graphite electrodes and fine carbon products. The Aluminum Sector provides aluminum materials and high-value-added fabricated aluminum, the Electronics Sector provides HD media, compound semiconductors such as ultra high bright LEDs, and rare earth magnetic alloys, and the Advanced Battery Materials Department (ABM) provides lithium-ion battery components. For more information, please visit www.sdk.co.jp/english/.

For further information, contact:
Showa Denko K.K., Public Relations Group, Brand Communication Department, Tel: 81-3-5470-3235


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comShowa Denko K.K. (SDK) (TOKYO: 4004) announces that it was resolved at the Board of Directors meeting held today that, regarding a plan for transformation from current company structure to holding company structure, the Company will start to consider the plan and prepare for execution of the plan.

TOKYO, Mar 9, 2022 - (JCN Newswire) - Showa Denko K.K. (SDK) (TOKYO: 4004) announces that it was resolved at the Board of Directors meeting held today that SDK will set the firm name of a new company (the newly integrated company) which is planned to be organized in January 2023 as a result of integration of SDK and Showa Denko Materials Co., Ltd. (SDMC), which is a member company of the Showa Denko Group, as in below. Execution of this resolution is subject to adoption of relevant resolutions by shareholders at an extraordinary general meeting of shareholders of Showa Denko K.K., which is planned to be held in late September 2022, and is also subject to adoption of relevant resolutions by shareholders at an extraordinary general meeting of shareholders of SDMC, which is planned to be held in late September 2022.

We will announce the details of this matter including changes in articles of incorporation as soon as they are decided.

1. Firm name of the Newly Integrated Company

Resonac Corporation

As stated in the news release titled "Showa Denko Group Starts to Consider Transformation into Holding Company Structure," which is announced at the same time today, we will consider transformation of our company structure from the current one into holding company structure. In this plan, we will set the current Showa Denko K.K. as a company to be split, execute the company split, make Showa Denko Materials Co., Ltd. (SDMC), which is a wholly owned subsidiary of HC Holdings K.K. (HCHD), in which SDK holds 100% of voting rights, succeed all businesses currently operated by SDK, and merge HCHD into SDMC. Then we will set SDMC as a company to be split, execute the company split, and make SDK succeed a part of SDMC's assets and liabilities.

If execution of this plan is finalized, firm names of the holding company and the manufacturing company will be set as follows.

- Holding company (current Showa Denko K.K. (planned)): Resonac Holdings Corporation
- Manufacturing company (current Showa Denko Materials Co., Ltd. (planned)): Resonac Corporation

2. Corporate logotype
https://www.acnnewswire.com/docs/Multimedia/Resonac_Logo.jpg

3. Reason for change in the firm names

In January 2023, SDK and SDMC will cooperatively transform themselves into a holding company structure, in which the holding company will specialize in formulating and executing group strategy, and functioning as a company listed on the stock exchange, and the newly integrated company (a company involved in manufacturing) will focus on strengthening competitiveness of each business of the Company in order to realize synergy of integration of SDK and SDMC as soon as possible, and operating businesses in a quick and flexible manner corresponding to the surrounding environment. The newly organized corporate group will aim to become a "Co-Creative Chemical Company," which will have global top-level competence as a chemical manufacturer, make decisions and act swiftly and flexibly, and co-create better society with key players in various industries and consumers who share a high aim and ideal with us. In order to take a new step as the newly integrated company and realize Co-Creative Chemical Company, we decided to change the new company's name into "RESONAC" concurrently with the integration of the two legal entities.

The Showa Denko Group sees the integration as "the second foundation" for SDK and SDMC. Under the new firm names, the brand-new Resonac Group will ferment the sense of unity further, create new functions required of the time as an advanced material partner, and contribute to sustainable development of global society.

4. Our hope put into the new firm name and corporate logotype

The new firm name "RESONAC" was created as a combination of two English words, namely, the word of "RESONATE" and "C" as the first letter of CHEMISTRY. Into RESONAC, we put our hope that the Group's wide-ranging and flexible advanced material technologies will be connected and resonate with our partners' various technologies and ideas to realize bright future, and the resonance will spread further to meet new partners, thereby creating a powerful surge that changes society.

To express this hope of ours, we put two parallel lines that rises steadily from left to right into the lower left of the first letter R in the new corporate logotype. These parallel lines symbolize co-creation borne by resonance, and also symbolize our strong will to spread the resonance further and challenge to realize bright future together with our partners.

5. The scheduled date of changes in firm names

January 1, 2023

About Showa Denko K.K.

Showa Denko K.K. (SDK; TSE:4004, ADR:SHWDY) is a major manufacturer of chemical products serving from heavy industry to computers and electronics. The Petrochemicals Sector provides cracker products such as ethylene and propylene, the Chemicals Sector provides industrial, high-performance and high-purity gases and chemicals for semicon and other industries, the Inorganics Sector provides ceramic products, such as alumina, abrasives, refractory/graphite electrodes and fine carbon products. The Aluminum Sector provides aluminum materials and high-value-added fabricated aluminum, the Electronics Sector provides HD media, compound semiconductors such as ultra high bright LEDs, and rare earth magnetic alloys, and the Advanced Battery Materials Department (ABM) provides lithium-ion battery components. For more information, please visit www.sdk.co.jp/english/.

For further information, contact:
Showa Denko K.K., Public Relations Group, Brand Communication Department, Tel: 81-3-5470-3235


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comShowa Denko K.K. (SDK) (TOKYO: 4004) announces that it was resolved at the Board of Directors meeting held today that SDK will set the firm name of a new company (the newly integrated company) which is planned to be organized in January 2023 as a result of integration of SDK and Showa Denko Materials Co., Ltd. (SDMC), which is a member company of the Showa Denko Group, as in below.

The post Top Ethereum Whales Holding These Altcoins! Shiba Inu Tops The List appeared first on Coinpedia - Fintech & Cryptocurreny News Media| Crypto Guide

The world’s wealthiest Ethereum (ETH) whales are presently stocking enormous quantities of one stablecoin and two other altcoins, according to blockchain tracker WhaleStats. More USD Coins (USDC), Circle’s dollar-pegged stablecoin, are now held by the top 500 Ethereum addresses than any other asset. USDC is worth $1.64 billion to the whales, accounting for 13.38 percent …

Four U.S. senators are introducing a bill to place sanctions on Russia’s gold. “This legislation would deter the purchase of Russian gold and close this loophole that allows the Russian Federation to soften the financial impact of sanctions,” the senators explained. “By sanctioning these reserves, we can further isolate Russia from the world’s economy and […]

Oslo (Norway)/Tokyo (Japan) and Basel (Switzerland)/Mannheim (Germany), Mar 9, 2022 - (JCN Newswire) - NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients' cytotoxic T-cells targeting a wide range of cancer-related antigens, today announced that the companies have signed an agreement under which NOI will acquire all of VAXIMM's neoantigen program assets.

Under the agreement, NOI will acquire VAXIMM's neoantigen vaccine-related patents, license the requisite manufacturing patents, and will take over several existing contracts with key collaborators and partners. Financial terms of the agreement have not been disclosed. In 2019, the companies entered into a strategic clinical trial collaboration agreement and an equity investment agreement to develop novel personalized neoantigen cancer vaccines. VAXIMM retains rights to its first-in-class oral T-cell activation platform technology and all other product candidates, including VXM01, which is being developed for the treatment of glioblastoma.

Commenting on the announcement, Richard Stratford, CEO of NOI, said, "We believe this is a transformative transaction for NOI/NEC. With it, NOI/NEC has acquired the rights to an attractive delivery platform with broad therapeutic potential in oncology and other areas. Following this acquisition, we expect to initiate the first clinical study delivering personalized neoantigens during 2022, which is an important milestone. Our unique artificial intelligence (AI) technology is focused on several attractive areas of unmet medical need with major market potential, and we now have the components in place to fully realize this significant commercial opportunity."

Thomas D. Szucs, MD, Chairman of the Board of VAXIMM, said, "I am excited to see the progress that has been made in advancing our neoantigen program, already with the strong support of NEC as partner and investor. I congratulate the VAXIMM team, under Dr. Lubenau's leadership, for bringing this important project to clinical testing stage. We are delighted that the NOI team will now take this program forward into the clinic with the goal of bringing a novel therapy to patients in desperate need of more treatment options."

Dr. Heinz Lubenau, CEO and Co-founder of VAXIMM, said, "We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen programs through development and hopefully to the market to help patients. The first project from our earlier collaboration utilizing NEC's AI platform has received clinical trial approval in Europe, and we are excited that NEC will be putting its resources behind this and future neoantigen vaccine programs derived from VAXIMM's novel technology."

Motoo Nishihara, Executive Vice President, CTO (Chief Technology Officer) and Member of the Board, NEC Corporation, said, "Cancer and infectious diseases are two of the most serious healthcare challenges, with millions of new cases diagnosed worldwide annually. NEC's core AI technology is well positioned for the development of personalized medicines, and we are strongly committed to delivering effective treatments for cancer patients and infectious diseases. We are confident that this acquisition of assets from VAXIMM will enable us to further develop our AI-optimized and personalized therapies to benefit the health of individual patients worldwide."

The transaction expands NEC's neoantigen drug development pipeline by broadening its focus into several compelling therapeutic areas with high unmet medical need. VAXIMM's plug and play DNA vaccination technology is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients' cytotoxic T-cells to target a wide range of cancer-related antigens. The platform allows for fast and scalable manufacturing of personalized T-cell cancer vaccines and may overcome key challenges faced by many other approaches.

About NEC OncoImmunity AS

NEC OncoImmunity AS is an AI driven biotechnology company that has developed proprietary machine learning-based software which addresses the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy, in addition to infectious disease vaccines. The AI technology can be used to identify optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy. For more information, visit NEC OncoImmunity AS at https://www.oncoimmunity.com/.

About NEC's AI Drug Development Business

For more information, please visit https://www.nec.com/en/global/solutions/ai-drug/

About NEC's Neoantigen Prediction System

NEC's neoantigen prediction system utilizes its proprietary AI, such as graph-based relational learning, trained on multiple sources of biological data to discover candidate neoantigen targets. These targets are carefully analyzed using proprietary machine learning algorithms that include in-house HLA binding and antigen presentation AI tools to evaluate the likelihood of eliciting a robust and clinically relevant T-cell response. With NEC OncoImmunity now onboard, NEC continues to strengthen its top class neoantigen prediction pipelines with the aim of maximizing the therapeutic benefits of personalized cancer immunotherapy for patients worldwide. For more information, visit NEC at www.nec.com.

About VAXIMM

VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM's plug and play DNA vaccination technology is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients' cytotoxic T-cells to target a wide range of cancer-related antigens. The Company has a pipeline of complementary development candidates targeting different tumor structures. Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer. VAXIMM has recently licensed its neoantigen program assets to NEC OncoImmunity, a subsidiary of NEC Corporation. VAXIMM's platform allows for fast manufacturing of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches. VAXIMM has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM's existing programs.

VAXIMM's investors include: BB Biotech Ventures, BCM Europe, BioMedPartners, CMS, M Ventures, NEC and CSV as well as Sunstone Life Science Ventures. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company's development activities. For more information, please visit www.vaximm.com.

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comNEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients' cytotoxic T-cells targeting a wide range of cancer-related antigens, today announced that the companies have signed an agreement under which NOI will acquire all of VAXIMM's neoantigen program assets.

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first commercial producer of ultra-low power neuromorphic AI chips and IP, today announced new sales partnerships in Europe and Israel that will further expand the commercial reach of its Akida™ neuromorphic computing platforms. The company has partnered with Eastronics, a large, […]

The post BrainChip Continues Expansion with Sales Partnerships in New Geographic Markets appeared first on Fintech News.

Federal authorities tracked down and seized more than 94,000 bitcoin allegedly stolen from Bitfinex. But how did they get their hands on the pseudonymous funds?

The global custodian’s tech needs are moving from the back office to the front, says its Hong Kong head.

The post Northern Trust seeks fintech help for ESG appeared first on Digital Finance.

The post Ethereum Set To Plunge Hard ! ETH Price May Drop Below $2k, Here are levels To Watch appeared first on Coinpedia - Fintech & Cryptocurreny News Media| Crypto Guide

As the new trading week begins in the United States, the price of Ethereum (ETH) rises dramatically. As it found reliable support around $2,500, the price of ETH may continue to rise in order to find important levels of resistance. Finally, Ethereum  is in a long-term bear market. However, before a definite directional bias, it …

Australian NFT platform Immutable announced that it has raised US$200 million in a Series C funding round led by Temasek, earning it a unicorn badge with a US$2.5 billion valuation.

The post Aussie NFT Platform Immutable Earns Unicorn Badge With US$200M Series C Led by Temasek appeared first on Fintech Singapore.

DUBLIN–(BUSINESS WIRE)–The “Electronic Health Record Market Research Report by Type, by Deployment, by End User, by Application, by Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Electronic Health Record Market size was estimated at USD 29.14 billion in 2020, is expected to reach […]

The post The Worldwide Electronic Health Record Industry is Expected to Reach $52 Billion by 2027 – ResearchAndMarkets.com appeared first on Fintech News.

LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Rafael Holdings, Inc. (“Rafael” or the “Company”) (NYSE: RFL) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Rafael investments […]

The post Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors appeared first on Fintech News.